Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule therapies to combat serious health issues, including oncology and obesity, recently announced equity inducement awards for two new employees as of August 1, 2025. These grants were made under the 2022 Employment Inducement Award Plan, reflecting the company's commitment to attract top talent in compliance with Nasdaq Listing Rule 5635(c)(4).

The awards included a significant option to purchase 500,000 shares of Terns common stock for Robin Andrulevich, who joins the company as Chief People Officer. Additionally, another non-executive employee received an option for 125,000 shares. Both options have a ten-year term and an exercise price set at $5.47 per share, which coincides with the closing stock price on the grant date. The options are designed to vest over four years, contingent upon the employees' ongoing service with the company.

Terns Pharmaceuticals is advancing a diverse pipeline that includes three clinical-stage development programs. Noteworthy among these are an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-? agonist, alongside a preclinical discovery initiative focusing on a GIPR modulator, with an emphasis on nominating a GIPR antagonist candidate.

This strategic move is indicative of Terns' efforts to bolster its leadership and expertise as it pushes towards significant clinical milestones. For further details, Terns encourages interested parties to visit their website or reach out to their investor and media contacts.

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) has recently made strategic equity inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4), signaling a potentially positive outlook for the company and its investors. The company’s decision to grant significant stock options to key personnel, including its new Chief People Officer, Robin Andrulevich, highlights its commitment to attracting and retaining top talent, which is crucial for a clinical-stage biopharmaceutical firm.

The options granted, with a total of 625,000 shares allocated between the two new employees, have an exercise price of $5.47 per share, reflecting the closing stock price on the grant date. This aligns employee interests with those of shareholders, incentivizing performance that could drive stock value higher over time.

Terns Pharmaceuticals is actively developing a diversified pipeline with focused areas addressing serious diseases, such as oncology and obesity. Their key candidates, including an allosteric BCR-ABL inhibitor and a small-molecule GLP-1 receptor agonist, position the company within high-demand therapeutic markets. Investors should closely monitor the progress of these developmental programs, as successful clinical outcomes could highlight the company’s potential and catalyze stock appreciation.

Moreover, the company’s commitment to long-term vesting schedules for the stock options (over four years) emphasizes stability and sustained performance, which can contribute positively to Terns’ business culture and operational execution.

Considering the developments, investors might view TERN as a speculative but promising buy, particularly for those willing to assess the risks involved in clinical-stage biopharmaceutical investments. It’s advisable to keep tracking progress in clinical trials and other corporate updates that could affect stock performance. As always, conducting thorough due diligence before making investment decisions is recommended.